Geron Corp. (NASDAQ:GERN) shares fell 2.5% on Thursday . The stock traded as low as $2.66 and last traded at $2.71, with a volume of 1,031,790 shares trading hands. The stock had previously closed at $2.78.

Several brokerages have weighed in on GERN. FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a report on Sunday, May 8th. Zacks Investment Research raised shares of Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 price objective for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $6.17.

The company has a market capitalization of $438.73 million and a P/E ratio of 920.00. The stock’s 50 day moving average is $2.68 and its 200 day moving average is $2.84.

Geron Corp. (NASDAQ:GERN) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.38 million. During the same quarter in the previous year, the business posted ($0.06) earnings per share. The company’s quarterly revenue was down 15.9% on a year-over-year basis. Equities analysts predict that Geron Corp. will post ($0.23) earnings per share for the current fiscal year.

A number of hedge funds have modified their holdings of GERN. Morgan Stanley boosted its stake in shares of Geron Corp. by 194.2% in the fourth quarter. Morgan Stanley now owns 268,626 shares of the biopharmaceutical company’s stock worth $1,300,000 after buying an additional 177,313 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Geron Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 292,950 shares of the biopharmaceutical company’s stock worth $1,418,000 after buying an additional 5,223 shares during the last quarter. Finally, Russell Frank Co acquired a new stake in shares of Geron Corp. during the fourth quarter worth $1,099,000.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.